1. Updates and Perspectives on Third-Generation EFGR TKIs in Advanced NSCLC

3. Third-Generation EFGR TKIs in Advanced NSCLC

4. Osimertinib

5. AURA Study: Phase 2 Expansion Cohort in First Line Patients Results

6. Osimertinib – Adverse Events

7. FLAURA Trial: Osimertinib vs Gefitinib or Erlotinib in Treatment-Naive Patients

8. EGFR C797S -- Resistance to Osimertinib

9. BLOOM Phase 1 Trial: Osimertinib Activity in Leptomeningeal Disease From NSCLC

10. BLOOM Phase 1 Trial -- Results

11. Olmutinib (BI 1482694) in Patients With T790M+ Advanced NSCLC

12. Olmutinib (BI 1482694) -- Results

13. Rociletinib for EGFR T790M+ NSCLC

14. ASP8273 (300 mg) in EGFR+ NSCLC: Interim Results

15. EGFR Exon 20 Insertions in NSCLC

16. EGF816: in EGFR Advanced NSCLC T790M+ Patients

17. Patients Who Have Progressed on Third-Generation EGFR TKIs

18. Ongoing Trials

19. Biomarker Testing in Advanced NSCLC

20. Applications of Liquid Biopsy

21. Limitations to Plasma-Based Testing

22. Conclusions

23. Abbreviations

24. Abbreviations (cont)